Miconazole Nitrate interactions
Checked as Miconazole in this data source.
Full monograph for Miconazole NitrateCheck it against another medicine
Medicines
374 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Glibenclamide | Major | Metabolism | Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the… | 35 sources — open the full entry |
| Glimepiride | Major | Metabolism | Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the… | 35 sources — open the full entry |
| Glimepiride + Metformin | Major | Metabolism · Unknown | Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the…2 documented mechanisms | 35 sources — open the full entry |
| Glipizide | Major | Metabolism | Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the… | 35 sources — open the full entry |
| Glipizide + Metformin Hydrochloride | Major | Metabolism · Unknown | Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the…2 documented mechanisms | 35 sources — open the full entry |
| Pioglitazone + Glimepiride | Major | Metabolism | Coadministration with inhibitors of CYP450 2C9 including certain azole antifungal agents such as fluconazole, miconazole, and voriconazole may increase the… | 35 sources — open the full entry |
| Warfarin Sodium | Major | Metabolism | Systemically or even topically administered miconazole may increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The proposed… | 54 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to… | 1 sources — open the full entry |
| Alprazolam | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of benzodiazepines… | 28 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to… | 1 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Metabolism | The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may… | 6 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Metabolism | The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may… | 6 sources — open the full entry |
| Amlodipine Besilate | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Moderate | Metabolism · Unknown | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 40 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 59 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Moderate | Metabolism · Unknown | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g…2 documented mechanisms | 40 sources — open the full entry |
| Apixaban | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both… | 2 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these… | 5 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to…2 documented mechanisms | 2 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA… | 19 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA… | 19 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Moderate | Metabolism | Coadministration with azole antifungal agents may increase the plasma concentrations of calcium channel blockers (CCBs), especially the dihydropyridines (e.g… | 40 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration of bosentan with a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 may result in increased plasma concentrations… | 1 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of brigatinib, which is partially metabolized by the isoenzyme. | 5 sources — open the full entry |
| BudesonideInhalerNebuliser SuspensionTablet | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide (Nasal Spray) | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide + Formoterol Fumarate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic… | 17 sources — open the full entry |
| Cabazitaxel | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme. | 1 sources — open the full entry |
| Cabozantinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. | 2 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased… | 8 sources — open the full entry |
| Cariprazine | Moderate | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl… | 3 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. Because ceritinib is… | 2 sources — open the full entry |
| Ciclesonide (Inhalation Aerosol) | Moderate | Metabolism | Coadministration of inhaled ciclesonide with potent inhibitors of CYP450 3A4 may increase systemic bioavailability of the pharmacologically active metabolite… | 6 sources — open the full entry |
| Ciclesonide (Nasal Spray) | Moderate | Metabolism | Coadministration of inhaled ciclesonide with potent inhibitors of CYP450 3A4 may increase systemic bioavailability of the pharmacologically active metabolite… | 6 sources — open the full entry |
| Cilostazol | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active… | 11 sources — open the full entry |
| Colchicine | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to… | 1 sources — open the full entry |
| Conjugated EstrogenCreamTablet | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 8 sources — open the full entry |
| Conjugated Estrogen + Bazedoxifene | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 8 sources — open the full entry |
| Crizotinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of crizotinib, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Cyclosporine (Oral) | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to… | 1 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Moderate | Metabolism | Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to… | 8 sources — open the full entry |
| Darifenacin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Dasatinib | Moderate | Metabolism | Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to… | 1 sources — open the full entry |
Conditions
Conditions in which Miconazole Nitrate needs care, as documented in this source.
Liver Diseases
ModerateThe use of miconazole in patients with liver disease has not been adequately studied, although it is known that miconazole is primarily metabolized by the liver. Therapy with miconazole should be administered cautiously in patients with liver disease, and the dosing adjusted or discontinued according to clinical response.
3 sources
- Lewi PJ, Boelaert J, Daneels R, et al. "Pharmacokinetic profile of intravenous miconazole in man." Eur J Clin Pharmacol 10 (1976): 49-54
- Daneshmend TK, Warnock DW "Clinical pharmacokinetics of systemic antifungal drugs." Clin Pharmacokinet 8 (1983): 17-42
- "Product Information. Monistat 7 (miconazole topical)." Ortho McNeil Pharmaceutical
Hyperlipidemias
MinorElevations in cholesterol and triglyceride levels may occur in patients receiving intravenous miconazole and are attributed to the drug vehicle, Cremophor EL (polyethoxylated castor oil). These increases are reversible upon discontinuation of miconazole therapy. Clinicians should be cognizant of these effects when interpreting lab results of hyperlipidemic patients during treatment with miconazole.
6 sources
- Naito HK, McHenry MC, Lewis LA "Drug-induced dyslipoproteinemia: a report of two cases." Clin Chem 26 (1980): 163-8
- Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS "Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections." Drugs 19 (1980): 7-30
- Rose HD, Roth DA, Barboriak JJ "Hyperlipidemia related to miconazole therapy." Ann Intern Med 91 (1979): 491-2
- Wade TR, Jones HE, Chanda JJ "Intravenous miconazole therapy of mycotic infections." Arch Intern Med 139 (1979): 784-6
- Bagnarello AG, Lewis LA, McHenry MC, Weinstein AJ, Naito HK, McCullough AJ, Lederman RJ, Gavan TL "Unusual serum lipoprotein abnormality induced by the vehicle of miconazole." N Engl J Med 296 (1977): 497-9
- "Product Information. Monistat 7 (miconazole topical)." Ortho McNeil Pharmaceutical